deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT04438005

A Study of ICP-022 in Patients With R/R DLBCL (DLBCL)

A Multicenter, Open-Label Study to Investigate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Conditions Diffuse Large B Cell Lymphoma
Interventions ICP-022
Updated 7 times since 2020 Last updated: May 9, 2024 Started: May 7, 2020 Primary completion: Nov 5, 2021 Completion: Dec 13, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diffuse Large B Cell Lymphoma and is currently completed. Beijing InnoCare Pharma Tech Co., Ltd. leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshotRecruiting~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotRecruiting~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshotRecruiting~Sep 2022 – ~Jun 2024 · 21 months · monthly snapshotRecruiting~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  4. Sep 2022 — Jun 2024 [monthly]

    Recruiting PHASE2

  5. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

▶ Show 2 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  2. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing InnoCare Pharma Tech Co., Ltd.
Data source: Beijing InnoCare Pharma Tech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations